Pharmacovigilance study of ramucirumab: A safety analysis based on the FDA adverse event reporting system
The commonly reported AEs of ramucirumab observed in real-world data are consistent with those listed on the drug label. Nevertheless, new suspicious AEs were identified. Enhanced clinical vigilance, through pretreatment risk assessment and ongoing posttreatment monitoring, is recommended to ensure patient safety.
Authors
- Zhen Liu (ORCID: https://orcid.org/0000-0002-9039-3762)
- Jian Xie (ORCID: https://orcid.org/0000-0001-9091-863X)
- Liyuan Yang (ORCID: https://orcid.org/0000-0002-9614-6519)
- Meijuan Song
Institutions
- Shandong Provincial QianFoShan Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Journal of Cancer Research and Therapeutics
- Published
- 2025-09-01
- DOI
- https://doi.org/10.4103/jcrt.jcrt_129_25
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00